Table 4. Efficacy outcomes by prior bortezomib or lenalidomide treatment and prior therapy line.

	Prior bortezomib exposure		No prior bortezomib exposure		Prior lenalidomide exposure		No prior lenalidomide exposure
	Kd (n=250)	Vd (n=252)	Kd (n=214)	Vd (n=213)	Kd (n=177)	Vd (n=177)	Kd (n=287)	Vd (n=288)
1–3 prior lines, n	250	252	214	213	177	177	287	288
Median PFS, months	15.6	8.1	NE	11.2	12.9	7.3	22.2	10.2
HR for progression, Kd vs Vd (95% CI)	0.56 (0.44–0.73)		0.48 (0.35–0.66)		0.69 (0.52–0.92)		0.43 (0.32–0.56)
ORR, %	71.2	60.3	83.6	65.3	70.1	59.3	81.2	64.6
1 prior line, n	97	98	134	131	51	45	180	184
Median PFS, months	18.7	8.7	NE	11.2	15.6	10.3	22.2	10.1
HR for progression, Kd vs Vd (95% CI)	0.48 (0.31–0.76)		0.43 (0.28–0.66)		0.62 (0.33–1.17)		0.41 (0.29–0.58)
ORR, %	78.4	64.3	83.6	65.6	82.4	64.4	81.1	65.2
2–3 prior lines, n	153	154	80	82	126	132	107	104
Median PFS, months	13.1	7.4	15.7	9.4	9.7	6.6	NE	10.4
HR for progression, Kd vs Vd (95% CI)	0.62 (0.45–0.85)		0.56 (0.36–0.89)		0.73 (0.53–1.01)		0.45 (0.29–0.70)
ORR, %	66.7	57.8	83.8	64.6	65.1	57.6	81.3	63.5

Abbreviations: CI, confidence interval; HR, hazard ratio; Kd, carfilzomib and dexamethasone; NE, not estimable; ORR, overall response rate; PFS, progression-free survival; Vd, bortezomib and dexamethasone.